Clearside Biomedical
Directory listingDirectory record status
These labels describe this UNITEMFG record. They do not guarantee current capabilities, certifications, capacity, quality, or fit for a specific job.
- Directory listing
- Listed
- Ownership
- Unclaimed
- Evidence reviewed
- Not recorded
- Last evidence review
- Not recorded
About
Clearside Biomedical is a pioneering biotechnology company headquartered in Alpharetta, Georgia, specializing in innovative suprachoroidal drug delivery technology for treating eye diseases. The company has achieved a significant milestone as the developer of the first FDA-approved therapeutic delivered into the suprachoroidal space with their flagship product XIPERE for macular edema associated with uveitis. Clearside Biomedical leverages their proprietary SCS Microinjector technology to deliver drugs precisely to the back of the eye, addressing the critical need for targeted treatment of retinal diseases. The company maintains an active clinical development pipeline, conducting trials across six different retinal diseases including wet age-related macular degeneration through their CLS-AX program. With over 10,000 injections performed using their patented delivery system, Clearside Biomedical has demonstrated substantial clinical experience and expertise in ocular drug delivery. Their comprehensive intellectual property portfolio and focus on precision medicine position them as leaders in the ophthalmic pharmaceutical sector. The company operates under the principle of delivering drugs at the site of disease, aiming to improve patient outcomes while potentially reducing systemic side effects associated with traditional treatment approaches.